You are here

Article Text

Article menu
Download PDFPDF
Letter
Laser induced chorioretinal venous anastomosis in ischaemic central retinal vein occlusion
  1. A K H Kwok1,2,
  2. V Y W Lee2,
  3. T Y Y Lai2,
  4. C Hon3
  1. 1Department of Ophthalmology, Hong Kong, Sanatorium and Hospital, Hong Kong, People’s Republic of China
  2. 2Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Hong Kong, People’s Republic of China
  3. 3Department of Ophthalmology, Queen Mary Hospital, Hong Kong, People’s Republic of China
  1. Correspondence to: Dr Alvin K H Kwok, Department of Ophthalmology, Hong Kong Sanatorium and Hospital, 2 Village Road, Happy Valley, Hong Kong; alvinkwok{at}hksh.com

https://doi.org/10.1136/bjo.87.8.1043

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Laser induced chorioretinal venous anastomosis (CRVA) has been advocated by McAllister and Constable as a treatment for non-ischaemic central retinal vein occlusion (CRVO).1 This technique potentially offers a means of permanently bypassing the site of obstruction to venous outflow, which is thought to occur in the region of the lamina cribrosa. In ischaemic CRVO, the visual prognosis is usually much poorer, with devastating complications like neovascular glaucoma and progressive macular ischaemia.2 In this prospective study, we investigated the feasibility of laser induced CRVA in eyes with ischaemic CRVO, in view of the possibility of avoiding or lessening these severe complications.

    Materials and methods

    The classification of ischaemic CRVO was based on the presence of 10 disc diameter or more of capillary non-perfusion in the fundus fluorescence angiography …

    View Full Text

    Footnotes

    • Financial and proprietary interest: nil.

    • Financial support: nil.